Venetoclax, a highly potent BCL-2 inhibitor, has transformed AML treatment paradigms by inducing apoptosis, or programmed cell death, in malignant cells. While many patients initially respond favorably, resistance almost invariably emerges, dramatically curtailing remission duration and survival rates. The persistence of AML despite such targeted interventions has baffled clinicians and researchers for years, prompting an intensive search for the biological underpinnings of this resistance.

The Rutgers-led team focused on the mitochondria, the powerhouse and apoptotic orchestrator of the cell, to uncover how AML cells dodge venetoclax-induced cell death. Using advanced electron microscopy combined with sophisticated genetic screening techniques, the investigators homed in on a mitochondrial protein called OPA1, a dynamin-like GTPase that tightly regulates mitochondrial inner membrane structure, particularly the morphology of cristae. These cristae folds play a vital role in controlling the release of cytochrome c, a pro-apoptotic factor critical for initiating the cell suicide cascade.

Their analysis revealed that AML cells resistant to venetoclax displayed markedly elevated levels of OPA1. This overexpression drives a remodeling of mitochondrial architecture, resulting in tighter and more abundant cristae folds. This morphological adaptation effectively sequesters cytochrome c within the mitochondria, halting its escape into the cytosol and thereby preventing apoptosis. This elegant, previously uncharacterized defense mechanism provides AML cells with a stealthy means to evade the otherwise lethal effects of venetoclax.

Validating these findings, the researchers scrutinized samples from AML patients. Those who experienced relapse after venetoclax therapy exhibited significantly narrower mitochondrial cristae compared to treatment-naïve patients, with the sharpest alterations observed in cells from patients who had received venetoclax specifically. This patient-derived data strongly corroborates the in vitro and animal model discoveries, underscoring the clinical relevance of OPA1-mediated mitochondrial remodeling in therapy resistance.

Harnessing this knowledge, the team turned to novel small-molecule inhibitors targeting OPA1. Two experimental compounds, developed by collaborators at the University of Padua, were employed in preclinical mouse models engrafted with human AML cells. When these inhibitors were administered in combination with venetoclax, survival times soared, more than doubling relative to animals treated solely with venetoclax. This combination therapy effectively dismantled the mitochondrial defense, restoring apoptotic pathways and eradicating resistant leukemia cells.

Intriguingly, the efficacy of OPA1 inhibition was observed across diverse AML subtypes, including those harboring p53 mutations—a genetic hallmark often linked to poor prognosis and refractory disease. This broad applicability bodes well for clinical translation, as p53-mutant leukemias represent a substantial proportion of resistant cases with limited therapeutic options.

Beyond simply reinstating apoptosis, OPA1 inhibitors appear to invoke additional lethal stress on AML cells. The absence of functional OPA1 imposes a metabolic vulnerability, with leukemia cells becoming heavily dependent on glutamine metabolism. Moreover, these cells showed increased susceptibility to ferroptosis, a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation. These multifaceted mechanisms suggest that OPA1-targeted therapy might subvert AML survival through converging pathways, enhancing therapeutic potency.

Importantly, safety assessments in murine models indicated that OPA1 inhibition does not adversely affect normal hematopoiesis, a critical consideration for any therapy targeting blood cancers. This selective impact on malignant cells lends optimism to the therapeutic window and potential tolerability in future human trials.

Despite these promising results, the journey from bench to bedside is just beginning. The current OPA1 inhibitors serve as lead compounds requiring substantial refinement, especially concerning pharmacokinetics such as solubility and bioavailability. The investigators anticipate developing third-generation inhibitors that will optimize these drug-like properties, paving the way for early-phase clinical studies in humans.

Senior author Christina Glytsou emphasized the transformative nature of these findings, suggesting that targeting mitochondrial morphology could herald a new frontier in combating AML and perhaps other malignancies. Given that OPA1 overexpression and mitochondrial adaptations have been implicated in resistance across multiple cancers, including breast and lung cancers, this strategy may have broad oncologic implications.

This study exemplifies the evolving appreciation of cancer cell metabolism and organelle dynamics as integral players in therapy response and resistance. By decoding the mitochondrial secrets exploited by cancer cells, the Rutgers team has illuminated innovative avenues for intervention that transcend traditional approaches centered exclusively on genetic mutations or surface antigens.

As the scientific community rallies to validate and extend these insights, OPA1 inhibitors stand out as a beacon of hope to overcome one of the deadliest hematologic malignancies. With every step toward overcoming resistance, the prospect of durable remissions and increased survival in AML moves closer to reality. Rutgers Cancer Institute’s leadership in this research underscores their pivotal role in pioneering transformative cancer therapeutics.

Subject of Research: Animals

Article Title: Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia

News Publication Date: 15-Oct-2025

Web References: http://dx.doi.org/10.1126/sciadv.adx8662

References: Glytsou et al., Science Advances, 2025, DOI: 10.1126/sciadv.adx8662

Keywords: Leukemia, Cancer, Mitochondria, OPA1, Venetoclax Resistance, Acute Myeloid Leukemia, Apoptosis, Mitochondrial Dynamics, Ferroptosis, Glutamine Metabolism

Mitochondria, often described as the powerhouses of the cell, generate adenosine triphosphate (ATP) through oxidative phosphorylation, supplying the energy required for cell proliferation and survival. AML cells exhibit aberrant mitochondrial dynamics and bioenergetics, due in part to the heightened metabolic demands posed by their rapid proliferation. Dr. Kirienko’s research has revealed that these cancerous cells impose an unsustainable burden on their mitochondria, leading to a breakdown in mitochondrial quality control mechanisms. This mitochondrial dysfunction presents an exploitable weakness: by precisely targeting these defective energy factories, it is possible to selectively induce apoptosis in AML cells while sparing healthy hematopoietic cells.

The foundation of this approach builds on Dr. Kirienko’s extensive expertise in mitochondrial metabolism and cellular stress response pathways. Her laboratory’s recent work, supported by a highly competitive Cancer Prevention and Research Institute of Texas (CPRIT) High Impact/High Risk grant, aims to leverage this mitochondrial vulnerability as a therapeutic entry point. The overarching goal is to develop drugs that disrupt mitochondrial function in AML cells, crippling their energy production, and triggering cell death with minimal collateral damage to normal tissues.

Collaborating closely with international and interdisciplinary experts, this project integrates the clinical insights of Dr. Natalia Baran, a leukemia specialist at University Hospital Bern in Switzerland, and the chemical biology proficiency of Dr. Scott Gilbertson, Professor of Chemistry at the University of Houston. Their collective expertise facilitates an innovative drug development pipeline that spans from molecular design and synthesis to functional assays using patient-derived AML samples. By incorporating genetic profiling to understand the heterogeneity in mitochondrial vulnerabilities across different AML subtypes, the team is moving beyond a generic “one-size-fits-all” paradigm toward personalized treatment regimens.

Dr. Baran emphasizes the significance of tailoring therapies based on the mutational landscape of each patient’s leukemia. The diversity among AML genomes means that drug responses can vary dramatically, underscoring the necessity of a precision medicine approach. This strategy involves screening patient-specific AML cells against candidate mitochondrial inhibitors to determine optimal drug combinations that maximize efficacy and minimize toxic side effects, thereby raising the therapeutic index.

Preclinical validation is a critical component of the research effort. The team employs murine xenograft models in which mice are engrafted with human AML cells to create a living system that closely recapitulates the human disease milieu. These in vivo models enable the researchers to evaluate not only the efficacy but also the pharmacokinetics and toxicity profiles of emerging mitochondria-targeting agents before advancing to clinical trials. Dr. Gilbertson highlights the indispensable nature of these translational studies, noting that in vitro assays alone cannot fully predict a compound’s behavior in complex biological systems.

Moreover, the approach seeks to surmount the challenge of drug resistance, a pervasive problem in AML treatment. Targeting mitochondrial dysfunction may incapacitate alternative metabolic pathways that leukemic cells activate to survive conventional therapies. This dual attack on cancer bioenergetics and metabolism could prevent or delay the evolution of resistant clones, thereby improving long-term patient outcomes.

A crucial element of this work is the broader implication for oncology. While AML serves as the primary focus, mitochondrial dysfunction is increasingly recognized as a hallmark of various cancers, including solid tumors that evade conventional therapeutics. The insights gained from this project could catalyze the development of a novel class of anticancer agents with efficacy extending beyond hematologic malignancies.

Dr. Kirienko articulates a vision of therapy that not only extends survival but enhances the quality of life by reducing treatment-related toxicity. Conventional AML therapies are notorious for their debilitating side effects, prompting many patients to endure prolonged hospitalizations and compromised immune function. By contrast, mitochondria-focused drugs have the potential to be more selective and less damaging to normal cells, thus mitigating these adverse effects.

The implications for patient care are profound. Annually, thousands of individuals in Texas alone receive a leukemia diagnosis, many confronting the stark reality of relapse or resistance to current treatment regimens. The development of safer, more effective therapeutics could transform these grim statistics, instilling hope among patients and clinicians alike.

As the team progresses, their research continues to illuminate the finely balanced choreography of mitochondrial function, cancer metabolism, and cellular stress. Their approach exemplifies a cutting-edge blend of basic science, translational research, and clinical insight, paving the way for paradigm-shifting cancer therapies.

In summary, by turning the cancer cells’ own energy generators into their Achilles’ heel, Dr. Kirienko and her collaborators are charting a visionary path toward precision oncology. The convergence of mitochondrial biology and targeted therapy heralds a new frontier in the fight against AML and possibly other refractory malignancies, signifying a beacon of hope for patients facing these devastating diseases.

Subject of Research:
Mitochondrial dysfunction as a therapeutic target in acute myeloid leukemia (AML)

Article Title:
Turning Mitochondria Against Acute Myeloid Leukemia: A Paradigm Shift in Cancer Therapy

News Publication Date:
Not specified

Web References:
https://profiles.rice.edu/faculty/natasha-kirienko
https://www.cprit.texas.gov/grants-funded/grants/rp250573
https://cprit.texas.gov/

Image Credits:
Jeff Fitlow/Rice University

Keywords:
Acute myeloid leukemia; AML; Cancer metabolism; Mitochondria; Targeted therapy; Drug resistance; Personalized medicine; Translational research; Cancer therapeutics